Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
Wednesday, 3 April 2024, 05:35
Genmab Acquires ProfoundBio
Genmab has recently made a significant announcement in acquiring ProfoundBio for USD 1.8 billion in cash. This acquisition marks a pivotal moment for Genmab's growth strategy in the oncology sector.
Enhancing Oncology Portfolio
This strategic move will broaden and strengthen Genmab's oncology portfolio, providing access to three new candidates with promising potential in cancer treatment.
- Global Rights: Genmab gains worldwide rights to the acquired candidates, expanding its reach in the global market.
- Competitive Advantage: The acquisition positions Genmab as a key player in the oncology landscape, enhancing its competitiveness and innovation.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.